To assess the degree of ethanol absorption and subsequent formation of urinary ethyl glucuronide (EtG) and ethyl sulfate (EtS) following sustained application of hand sanitizer, 11 volunteers cleansed their hands with Purell™ hand sanitizer (62% ethanol) every 5 min for 10 h on three consecutive days. Urine specimens were obtained at the beginning and end of each day of the study, and on the morning of the fourth day. Urinary creatinine, ethanol, EtG, and EtS concentrations were measured. EtG was undetectable in all pre-study urine specimens, but two pre-study specimens had detectable EtS (73 and 37 ng/mL). None of the pre-study specimens had detectable ethanol. The maximum EtG and EtS concentrations over the course of the study were 2001 and 84 ng/mL, respectively, and nearly all EtG-and EtS-positive urine specimens were collected at the conclusion of the individual study days. Only two specimens had detectable EtG at the beginning of any study day (96 and 139 ng/mL), and only one specimen had detectable EtS at the beginning of a study day (64 ng/mL), in addition to the two with detectable EtS prior to the study. Creatinine-adjusted maximum EtG and EtS concentrations were 1998 and 94 μg/g creatinine, respectively. In patients being monitored for ethanol use by urinary EtG concentrations, currently accepted EtG cutoffs do not distinguish between ethanol consumption and incidental exposures, particularly when urine specimens are obtained shortly after sustained use of ethanolcontaining hand sanitizer. Our data suggest that EtS may be an important complementary biomarker in distinguishing ethanol consumption from dermal exposure.
Introduction
Certain individuals, including physicians and nurses in substance use recovery programs, are required to abstain from the consumption of ethanol. Although blood or breath ethanol measurements traditionally have been the most useful forensic indicators of ethanol use, urinary metabolites of ethanol have emerged as key components of abstinence monitoring in these programs. Because it is rapidly metabolized, ethanol measured in blood or urine only reveals recent use, and therefore, it is an insensitive indicator of abstinence. Ethyl glucuronide (EtG) and ethyl sulfate (EtS) have longer half-lives than ethanol and, consequently, are useful biomarkers of ethanol use. These metabolites represent less than 1% of an ethanol dose and are produced by mitochondrial UDP-glucuronosyltransferase and cytosolic sulfotransferase, respectively (1) . A recent study has demonstrated that EtG may be detectable in the urine for at least 130 h (at a positive threshold of 500 ng/mL) and EtS may be detectable in the urine for at least 110 h (at a positive threshold of 100 ng/mL) after last ethanol consumption in heavy drinkers (2) .
Recently, incidental exposures to ethanol (e.g., ethanol-containing hand sanitizers and mouthwashes) have been shown to produce quantities of urinary EtG less than 350 ng/mL (3) . Most monitoring programs use empirically adjusted upper limits of 500 or 1000 ng/mL for EtG in urine, above which incidental exposure is not considered a legitimate explanation for the production of these biomarkers (4, 5) . Unlike EtG, EtS, a more recently introduced biomarker of ethanol consumption, is not susceptible to false-positive results due to post-collection bacterial synthesis (6) . EtS cutoffs, however, are not yet universally agreed upon. Our group and others have encountered monitored health professionals who have produced urinary concentrations of EtG that exceeded 500 ng/mL, claiming it was due to intensive occupational exposure to ethanol-containing hand sanitizer. Moreover, an account of a nurse whose urinary concentration of EtG was 770 ng/mL after intensive hand washing with an ethanol-based cleanser in a secured treatment facility has appeared in The Wall Street Journal (7) .
An important unanswered clinical and forensic challenge is determining the appropriate threshold concentrations of ethanol biomarkers that are sufficiently sensitive to detect ethanol consumption, but specific enough to eliminate the possibility of false accusations that may be a result of incidental exposures. The purpose of this study was to determine the highest concentrations of EtG and EtS that could be produced with intensive use of an ethanol-containing hand sanitizer.
Materials and Methods

Study protocol
This study was conducted in a conference room at the University of Florida Health Science Center/Jacksonville. The protocol was approved by the University of Florida Institutional Review Board (UFJ 2010-028), and informed consent was obtained from all study participants. Participants were recruited with posted advertisements at the medical center and through personal communications with the investigators. The participants included three females and eight males. The study participants were compensated for taking part in the project.
Study participation was offered to individuals between the ages of 18 and 70, inclusive. Any history of ethanol use disorder, obsessive-compulsive disorder involving hand washing, xerodermia, skin sensitivity to ethanol, hepatic or renal dysfunction, diabetes mellitus, and symptoms of urinary tract infection were exclusionary criteria. Subjects were required to abstain from ethanol use for five days prior to the study. An a priori requirement for inclusion was that the first urine specimen collected must be negative by conventional criteria (EtG and EtS less than 500 ng/mL) for ethanol use.
Twelve subjects were recruited for the study; one was excluded on the day prior to the study because of ethanol consumption within the previous two days. Eleven subjects were enrolled and completed the study. On Day 1, the subjects provided a first morning void urine specimen. Subjects then proceeded to a conference room and cleansed their hands with Purell hand sanitizer (62% ethanol) every 5 min for a 10-h period. Subjects were instructed to use one pump (delivering approximately 1 mL) of hand sanitizer and to rub their hands together briskly for 30 s; any unabsorbed sanitizer was allowed to evaporate. At the end of the study period, subjects provided a second urine specimen before leaving the facility. The same procedure was followed on Days 2 and 3. On Day 4, all subjects provided a first morning void urine specimen, concluding their participation in the study. All urine specimens were frozen at -20°C within 30 min of collection.
Analytical methods
High-performance liquid chromatography (HPLC)-grade water and acetonitrile were obtained from VWR (Westchester PA). Ethanol in urine was measured using the Microgenics DRI Ethyl Ethanol Assay (Microgenics, Fremont, CA). The assay was set up according to the manufacturer's specifications. The lower limit of quantitation is 20 mg/dL, and the method is linear to 350 mg/dL.
Creatinine in urine was measured by the Jaffe picric acid method with reagents obtained from Microgenics (DRI Creatinine-Detect-Test) with a linear range of 0.21 to 350 mg/dL.
Calibrators were prepared from 100 µg/mL EtG or EtS in methanol, obtained from Lipomed (Cambridge, MA), and subsequently diluted in HPLC-grade water to the concentrations of 100, 500, 1000, 2000, 5000, or 10,000 ng/mL. EtG-d 5 and EtS-d 5 internal standards (100 ng/mL) in methanol were obtained from Lipomed and diluted to working concentrations in HPLC-grade water.
A "dilute and shoot" LC-MS-MS measurement for EtG and EtS quantitation in subject urine samples was developed by Millennium Research Institute (San Diego, CA). All EtG and EtS assays were performed on an Aria Transcend multiplexing LC system paired with a Quantum Ultra triple-stage quadrupole mass spectrometer and Xcalibur™ software (Thermo Fisher Scientific, Waltham, MA).
Mass spectra were collected using electrospray ionization with the ion source operating in negative ion mode. The optimized instrumental parameters were as follows: spray voltage 3500 V, vaporizer temperature 375°C, sheath gas 25 kPa, auxillary gas 10 kPa, capillary temperature 350°C, tube lens 90 V, skimmer offset 10 V, and collision pressure 1.3 millitorr. Multiple reaction monitoring (MRM) mode was used for quantitation.
In MRM mode, two transitions are used to analyze a single compound. A quantitative transition was used to calculate concentration based on the quantifier ion and a qualitative transition was used to ensure accurate identification of the target compound based on the ratio of the qualifier ion to the quantifier ion. The quantitative transition used for EtG was 221 → 75 with collision energy set to 15 V. The qualitative transition was 221 → 85 with collision energy set to 17 V. The transition used for EtG-d 5 was 226 → 75 with collision energy set to 15 V. The quantitative transition used for EtS was 125 → 97 
Method LC-MS-MS LC-MS-MS Linear range
100-10,000 ng/mL 100-10,000 ng/mL Interday precision (% CV) 8% 4% Interday accuracy (% Bias) 11% 7%
* The accuracy of the assay was determined by quantitation of EtG and EtS in quality control samples prepared in synthetic urine at concentrations of 750 ng/mL for EtG and 200 ng/mL for EtS. Interday precision and bias were determined by repeating the assay (n = 20). † EtS linearity and bias was also assessed between 10 and 100 ng/mL. The average bias for urine specimens containing 10 ng/mL EtS was 23%, and was less than 20% at 50, 70, and 100 ng/mL. with collision energy set to 18 V. The qualitative transition was 125 → 80 with collision energy set to 36 V. The transition used for EtS-d 5 was 130 → 98 with collision energy set to 19 V. The scan interval was set to 0.05 s.
Quantitative analysis was performed using LC Quan software (Thermo Scientific). A five-point calibration curve was created using a linear fit model with 1/x weighting and ignoring the origin.
The precision of the EtG assay was determined using two quality control preparations provided with the Microgenics EtG immunoassay, and precision of the EtS assay was determined with an inhouse control prepared with a concentration of 200 ng/mL. The day-to-day coefficients of variation of the EtG assay were 8% and 3% at 625 and 1250 ng/mL, respectively, and 7% at 200 ng/mL for the EtS assay, using quantitative values from three independent batches per day obtained over five days. The EtG and EtS assay had interday coefficients of variation of 7% and 4%, respectively, at their lower limits of quantitation. The analytical performance characteristics for the EtG and EtS confirmatory assay are summarized in Table I .
The performance characteristics of the EtS assay were assessed below the 100 ng/mL threshold. Three sets of five EtS calibrators with concentrations of 10, 50, 70, and 100 ng/mL (a total of 15 samples at each concentration) were prepared in EtS negative (patient) urine, and the mean analytical biases for the 15 calibrators at each concentration were 23%, 14%, 18%, and 17%, respectively.
Results
Urine EtG, EtS, and creatinine results are presented in Table II . None of the subjects had detectable EtG in their urine at the beginning of the study, although two had detectable concentrations of EtS. Ethanol concentrations in all specimens were below the quantitation threshold of 20 mg/dL.
The mean EtG concentration across all subjects and specimens (excluding prestudy specimens) was 278 ng/mL, and the 95th and 99th percentiles were 1037 and 1645 ng/mL, respectively. The corre- 0  0  138  0  0  B  552  0  46  1195  0  C  96  0  204  47  0  D  877  0  80  1104  0  E  139  0  197  71  0  F  553  0  40 sponding mean, 95th, and 99th percentiles for EtG adjusted to a creatinine of 100 mg/dL (ng/mL/100 mg creatinine/dL = µg/g creatinine) were 351, 1302, and 1692 µg/g creatinine, respectively.
The highest concentrations of EtG were observed at the end of each study day, following use of the hand sanitizer 120 times over 10 h. One subject reached a urine EtG concentration of 2001 ng/mL at the end of the third day of the study. The mean urinary EtG concentrations at the end of Days 1, 2, and 3 were 493, 601, and 542 ng/mL, respectively, with a range of 0-2001 ng/mL. The creatinine-adjusted maximum EtG was 1528 µg/g creatinine, and the mean urinary EtG at the end of study Days 1, 2, and 3 was 546, 823, and 707 µg/g creatinine, respectively. One subject had detectable concentrations of EtG in the first morning urine on Days 2 and 3 (96 and 139 ng/mL, or 47 and 71 µg/g creatinine, respectively), and EtG was detected in the post-study morning urine of another subject (138 ng/mL, or 112 µg/g creatinine).
With the exception of one subject, who remained EtG-negative throughout the study, all subjects had at least one urine specimen with a detectable concentration of EtG. Only four subjects produced an EtG-negative urine (at a 50 ng/mL positive threshold) at the end of a study day, immediately after 10 h of exposure to the hand sanitizer. Three subjects never exceeded 500 ng/mL total urinary EtG, but only two were consistently below a 500 µg/g creatinine threshold.
Because none of the EtS concentrations exceeded the limit of quantitation (100 ng/mL), the performance of the assay below 100 ng/mL was assessed, in order to validate quantitative EtS measurements in the range observed in the study subjects. The performance of the EtS method below 100 ng/mL did not uniformly satisfy the customary criteria for the limit of quantitation (analytical bias ≤ 20%) because the average bias at a concentration of 10 ng/mL was 23%. Therefore, the quantitative EtS data are reported with the caveat that the analytical bias may exceed 20%, particularly at the lower concentrations.
EtS was detected in fewer of the study subjects than EtG, but curiously, two of the subjects had detectable EtS (but not EtG) in their pre-study specimens. Mean, 95th, and 99th percentile EtS concentrations for all specimens (excluding prestudy specimens) were 9, 60, and 75 ng/mL, respectively. Corresponding creatinine-adjusted mean, 95th, and 99th percentiles were 9, 61, and 91 µg/g creatinine, respectively. Three subjects never produced detectable EtS in their urines, and the maximum EtS concentration detected in any of the urines was 84 ng/mL; the maximum creatinine-corrected EtS concentration was 94 µg/g creatinine (in another subject). Six of the 11 subjects had urinary EtS concentrations above 50 ng/mL, but only 4 exceeded 50 µg/g creatinine. At a screening threshold of 100 ng/mL EtG, one of the specimens was negative, but had a confirmed EtG concentration of 137 ng/mL by LC-MS-MS. Two specimens produced screening results near or slightly above the threshold (98 and 110 ng/mL) but did not have detectable EtG concentrations by LC-MS-MS.
Statistical data for urine EtG, EtS, and creatinine are summarized in Table III .
Discussion
Current EtG cutoffs for detecting ethanol use (most commonly 500 or 1000 ng/mL) are based largely on industry recommendations, with little supporting scientific data. There are even fewer scientific data addressing the roles of urinary ethanol and EtS for this purpose (Table IV) .
In the single peer-reviewed study we identified (8), 9 subjects cleansed their hands with Avagard D™ hand antiseptic (1 mL; 61% ethanol) 20 times daily for 5 consecutive days. First morning urine specimens were collected on each study day, and for seven consecutive post-study days. EtG was present at baseline on the first study day (range: < 10 to 62 ng/mL) in 8 of 9 subjects. Two subjects produced a total of three urine specimens with detectable EtG during the study period (maximum: 114 ng/mL). Urinary ethanol, EtS, and creatinine were not measured.
A Letter to the Editor (5) described a study involving three groups of subjects who cleansed their hands with Germ-X™ hand sanitizer (62% ethanol; volume not specified) for a single 8-h day: Group 1 (n = 3), Group 2 (n = 4), and Group 3 (n = 2) cleansed every 60, 30, and 15 min, respectively. Urine was collected prior to exposure, at 3 h, and at the end of the study day. Urinary ethanol was not detected in any of the specimens. In Groups 1 and 2, urinary EtG never exceeded 50 ng/mL. In Group 3, one subject produced a urinary EtG concentration of 62 ng/mL. Neither EtS nor creatinine was measured.
A report appearing in The Wall Street Journal (7) described a case in which a nurse, who was enrolled in an impaired professionals monitoring program, had her nursing license suspended following a "failed" urine EtG test (the urinary EtG concentration was not specified). At the suggestion of the reporting physician, she was given the opportunity to demonstrate that a positive urine EtG test could, as she asserted, be due to intensive hand cleansing with an ethanol-based hand sanitizer. The subject was sequestered in a secured drug treatment facility and allowed to cleanse her hands "repeatedly during the day" (the frequency was not specified) with Purell hand sanitizer (62% ethanol; the volume was not specified). On the mornings before and following the experiment, EtG was undetectable in her urine. However, on the evening after ad libitum exposure to the hand sanitizer, she produced a urinary EtG concentration of 770 ng/mL. Ethanol, EtS, and creatinine were not measured.
An article in a non-peer-reviewed publication reported a two-part study involving two subjects dermally exposed to ethanol (9) . In the first part, both subjects cleansed their hands with Purell hand sanitizer (0.5 g; 62% ethanol) once hourly for an 8-h period. Urine specimens were collected at 2, 4, 6, and 8 h during exposure and the next morning. Ethanol, EtG, and EtS were measured in each urine specimen. For both subjects, urinary ethanol was undetectable in all voided specimens. In Subject A, EtG remained below the limit of detection throughout the study; the maximum EtS was 26 ng/mL and the maximum corrected EtS was 16 µg/g creatinine. In Subject B, the maximum EtG was 103 ng/mL (58 µg/g creatinine) and maximum EtS was 51 ng/mL (20 µg/g creatinine). In the second part of the study, involving only Subject A, hand cleansing was conducted with a larger quantity of sanitizer (2.0 g) for an 8-h period. The quantity of sanitizer necessitated cleansing to the level of the elbows. Urine was collected at 3, 6, 9, and 20 h. The maximum EtG (corrected for creatinine) of 799 µg/g (uncorrected EtG = 184 ng/mL) was measured at 3 h, and the maximum EtG was 713 ng/mL (557 µg/g creatinine) was measured at 9 h. An EtG of 551 ng/mL (333 µg/g creatinine) was measured the following morning. The maximum EtS was 14 ng/mL (and 29 µg/g creatinine).
The most notable finding in the present study is that intensive use of ethanol-containing hand sanitizer can yield urinary concentrations of EtG (and creatinine-corrected EtG) markedly higher than has been previously reported. Eight of our 11 subjects produced urinary EtG concentrations above 500 ng/mL; 4 subjects produced EtG concentrations above 1000 ng/mL; and 1 subject produced a urinary EtG concentration exceeding 2000 ng/mL. Normalized to 100 mg of creatinine, eight subjects produced EtG values above 500 µg/g; five of the subjects produced EtG concentrations above 1000 µg/g; and two of the subjects produced creatinine-adjusted EtG concentrations exceeding 1500 µg/g creatinine. The other notable finding of our study was that no subject produced a urinary EtS ≥ 100 ng/mL (or EtS ≥ 100 µg/g creatinine). This finding was consistent with the results of Jones et al. (9) noted previously. Millennium Research Institute extracted all confirmed positive urinary EtG and EtS data from chronic pain patients for December 2009. Of 590 specimens with EtG concentrations > 500 ng/mL, we examined the 298 specimens with EtG concentrations between 500 and 2000 ng/mL. Of these, 281 (94.3%) were associated with EtS ≥ 100 ng/mL. A reasonable assumption is that few (if any) of those specimens originated from hundreds-of-times-a-day users of ethanol-based hand sanitizers. We hypothesize that sulfation of ethanol may be a pathway that produces significant quantities of EtS only when the ethanol concentration is high enough to saturate alcohol dehydrogenase and glucuronosyl transferase pathways. If that is the case, then the EtG/EtS ratio might be useful in discriminating between ethanol consumption and incidental exposure to ethanol-containing products. In the Millennium cohort, EtG/EtS ratios were > 9 in only 6% of patients. In our abstinent study group, exposure to ethanol was casual, and the EtG/EtS ratios were > 9 in 100% of subjects. This same reasoning may explain why two of the subjects had detectable quantities (although well below the 500 ng/mL threshold) of EtS in their pre-study urine; these may represent residual EtS in subjects who had used ethanol prior to the 5-day abstinence period preceding the study.
The small quantities of ethanol detected in this study were below the quantifiable limit of 20 mg/dL, although precision studies with ethanol-free controls in this laboratory revealed that some of the measured urinary ethanol concentrations were slightly above a 99% statistical threshold for background noise using the enzymatic ethanol assay. We suspect that the very low detectable concentrations of urinary ethanol were likely due to either endogenous production of ethanol or dermal absorption. However, none of the ethanol results would have been reported by the laboratory because they all were below the limit of quantitation, and the low detectable quantities of ethanol in some of the urine specimens do not suggest that urinary ethanol is a useful marker for dermal exposure.
In agreement with the study performed by Rosano and Lin (8), our results do not indicate that daily accumulation of EtG or EtS occurs. Likewise, our results are in agreement with Jones et al. (9), as we found that EtG concentrations exceeded EtS levels in 9 of 11 subjects, including 74 of 77 (96%) of all urine specimens collected in this study, and 69 of 70 (98.6%) non-baseline specimens. There was no apparent relationship between the concentrations of EtG and EtS in our study.
One of the participants failed to produce detectable quantities of EtG throughout the study, in contrast to the other subjects who consistently had detectable urinary EtG at the end of each study day. The possibility of an analytical interference was considered, and the urine specimens from that subject were screened for a wide variety of drugs, but nothing helpful was revealed. Clinically benign deficiencies in hepatic glucuronidation exist (Criglar-Najar Syndrome Type II; Gilbert's Disease), and it is possible that this subject expressed a genetic polymorphism that resulted in impaired capacity to produce EtG. However, the IRB-approved protocol did not permit further investigation of this possibility, because specimens were de-identified after collection to preserve subject anonymity.
Finally, this study does not rule out the possibility that the principal route of ethanol exposure was from inhalation of ethanol volatilized during use of the hand sanitizer, rather than dermal absorption. Researchers at our institution have found transient, dramatic spikes of ethanol after use of hand sanitizer using a breath-based technology (D. Dennis, M.D., personal communication). In any event, the currently accepted EtG thresholds of 500-1000 ng/mL are not adequate to distinguish between intentional ethanol use and incidental exposure in circumstances that involve frequent use of ethanolbased hand sanitizers. EtG in conjunction with EtS, however, appears to be a promising combination of biomarkers to distinguish ethanol consumption from sustained dermal exposure.
Conclusions
Intensive exposure to ethanol-containing hand sanitizer can produce urinary EtG concentrations in excess of 2000 ng/mL, or two-to fourfold greater than commonly accepted threshold concentrations used to identify ethanol consumption. False accusations of ethanol consumption can have catastrophic consequences for individuals being monitored in programs that require abstinence. The urinary EtG concentrations that may occur with intensive dermal exposure suggest that more moderate exposures are also likely to yield urinary EtG concentrations that exceed 500 ng/mL. These data, which reflect urinary ethanol metabolite concentrations under circumstances that simulate reasonable scenarios for healthcare professionals who cleanse their hands between patient contacts, demonstrate that significant dermal (and/or respiratory) absorption of ethanol occurs, and that use of ethanol-containing hand sanitizers can produce urinary concentrations of EtG that, by current standards, may be interpreted as deliberate ethanol use. Limited data indicate that neither raw nor corrected EtS concentrations exceed 100 ng/mL with dermal ethanol exposure. Further work is needed to define the roles, ratios, and cutoff values necessary to make EtG and EtS useful markers of ethanol exposure and consumption.
